Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation

A Randomized Double-blinded Controlled Trial Comparing Dilation and Evacuation Outcomes With and Without Oxytocin Use

Currently, there is very little research to identify ways to decrease blood loss during D&E (dilation and evacuation) procedures. The objective is to determine whether routine use of intravenous oxytocin will improve bleeding outcomes at the time of D&E at 18-24-weeks gestation. To evaluate the hypothesis, investigators will perform a randomized, double-blinded, placebo-controlled trial. The patient will be followed until discharged from the postoperative care unit during which time patient satisfaction, pain score and postoperative bleeding will be assessed.

Inclusion Criteria:

• Requesting pregnancy termination
• Intrauterine pregnancy at 18- to 24-weeks gestation
• Gestational-age to be confirmed by ultrasound
• Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to 24-weeks gestation
• Willing and able to understand and sign written informed consents in English or Spanish and comply with study procedures

Exclusion Criteria:

• Ultrasound findings suggestive of placenta accreta
• Patients requiring preoperative misoprostol